Half-year report · Q2
2160.TEDINET S100WJCL
Period2025-01-01 → 2025-06-30
Filed2025-08-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.3bn | 2025-01-01 → 2025-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥23.6bn | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥11.7bn | 2024-01-01 → 2024-06-30 | Cons. | Revenue IFRS |
| Operating income | −¥1.2bn | 2025-01-01 → 2025-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.8bn | 2024-01-01 → 2024-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥1.4bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥238m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥831m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥915m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.1bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥330m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥2.3bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss IFRS |
| Net income | −¥10m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥74m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥67.7bn | at 2025-06-30 | Cons. | Assets IFRS |
| Total assets | ¥71.9bn | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥69.0bn | at 2024-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥29.4bn | at 2025-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥32.2bn | at 2024-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥38.3bn | at 2025-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥39.7bn | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥40.0bn | at 2024-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥36.5bn | at 2023-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥35.3bn | at 2025-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥36.4bn | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥36.8bn | at 2024-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥10.5bn | at 2025-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥10.1bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥16.3bn | at 2024-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥21.6bn | at 2023-12-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥932m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥3.2bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥1.5bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥632m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥10.4bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥5.5bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥1.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥694m | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥186m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-18.19 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥21.96 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥6.61 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-18.19 | 2025-01-01 → 2025-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥21.15 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥6.37 | 2024-01-01 → 2024-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 52.1% | at 2025-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.7% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 53.4% | at 2024-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥4.1bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥4.1bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥503m |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥8.2bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥8.2bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥1.7bn |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥12.3bn |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥12.3bn |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | −¥1.2bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥2.6bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥2.6bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥676m |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥9.1bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥9.1bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥1.1bn |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥11.7bn |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥11.7bn |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | ¥1.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 716
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember | 502923000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | -1179539000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | -1179539000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 539301000 | JPY |
| Finance costs IFRS | CurrentYTDDuration | 794831000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration | 1118000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | -1433950000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-08-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第25期中（自 2025年１月１日 至 2025年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社ジーエヌアイグループ | |
| Company name in english cover page | FilingDateInstant | GNI Group Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)取締役代表執行役社長兼CEO イン・ルオ | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋本町二丁目２番２号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)03（6214）3600（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役執行役副社長ＣＯＯ兼ＣＦＯ 松井 亮介 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋本町二丁目２番２号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03（6214）3600（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役執行役副社長ＣＯＯ兼ＣＦＯ 松井 亮介 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05712 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 21600 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社ジーエヌアイグループ | |
| Filer name in english | FilingDateInstant | GNI Group Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2025-01-01 | |
| Current period end date | FilingDateInstant | 2025-06-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Comparative period end date | FilingDateInstant | 2024-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2024-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |